Zhejiang Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults

  NCT07935291· Phase 1· Nanjing Immunophage Biotech Co., Ltd· Source

• Not yet recruiting

  OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)

  NCT07855614· Zhejiang Hospital· Source

• Not yet recruiting

  Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD

  NCT07665359· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  24-Week Recurrence Rate of Gout Following Firsekibart Treatment

  NCT07625514· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial

  NCT07616531· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.

  NCT07059871· Zhejiang Hospital· Source

• Not yet recruiting

  Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer

  NCT07188116· Zhejiang Hospital· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

  NCT06863545· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension

  NCT07051811· Lepu Medical Technology (Beijing) Co., Ltd.· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease

  NCT06218485· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

  NCT06249750· Phase 2· Pengyuan Liu· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  NCT05869903· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

  NCT05686642· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors

  NCT07793214· Zhejiang Hospital· Source

• Active, not recruiting

  Long-term Efficacy and Safety Study of GV-971

  NCT05181475· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source

• Recruiting

  MR Microstructural Imaging for Prostate Cancer Diagnosis

  NCT07249281· First Affiliated Hospital of Zhejiang University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Bronchiectasis2 recruiting
• Childhood cancers2 recruiting
• Coronary artery disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Gout2 recruiting
• Prostate cancer2 recruiting
• COPD1 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Obesity1 recruiting
• Schizophrenia1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

  NCT06054698· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Completed

  A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06045221· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

  NCT05362058· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study on the Effectiveness Evaluation in Stroke Patients Using Lower Limb Assistive Walking Devices

  NCT06564480· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms

  NCT04289480· Medos International SARL· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Diabetic eye disease20 works · 0 trials
• Hepatitis B8 works · 0 trials